06 September 2018
A new report by visiongain forecasts the world cell-based assay market will reach $6.9bn in 2020. That revenue prediction and others appear in Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME and Basic Research, published in May 2016. Visiongain is a business information publisher and consultancy in London, UK.
The analysis predicts the global cell-based assays market will continue to grow at a CAGR of 12.4% from 2015-2020, driven by the products and drug discovery segments. In 2015, drug discovery will be the leading market application of cell-based assays with revenues of $2.5bn. Drug discovery will remain as the leading market application throughout the coming decade.
Demand for the market will be fuelled by requirements within the pharmaceutical industry to reduce the failure rates of clinical trials dedicated to finding new therapeutic compounds. Such trials are limited by the effectiveness of the assays available for investigation of new drugs. This is where the latest cell-based assay technology, covered in this report, will excel over the next 10 years.
Robert King, a pharmaceutical and healthcare industry analyst in visiongain, said:
“New technological advances in the cell-based assay industry will see it go from strength-to-strength over the next decade. The advantages they hold over traditional animal based methods in drug development and diagnostics have led to growing demand. Failure rates in clinical trials have been high in the past two decades, with many (just under a third) resulting from issues with toxicity and safety. Given this, cell-based assays have become the preferred tool for screening potential drug compounds and toxicity screening. Organisations require effective early models for predicting toxicity, in order to reduce the risk of late-stage failure, which can cost companies millions of dollars. This is a huge driver for the cell-based assays market.
The last decade has seen the rapid increase in the application of cell-based assays among the pharmaceutical and academic industries and, according to visiongain’s forecasts, this rapid growth is set to continue over the next ten years. Advanced Cell-Based Assays, which utilise 3D cellular environments, are the latest development within the industry. These latest developments will create new opportunities in applications, services and products”.
This report investigates commercial trends and revenues of the cell-based assay market from 2016 to 2026, as well as including data from 2015. This report discusses sales potentials of:
• The market divided into two key ways:
o By services and products
o By application
ADME (absorption, distribution, metabolism and excretion)
• 11 leading individual national markets including:
o EU5 (Germany, France, UK, Italy and Spain)
o BRIC (Brazil, Russia, India and China)
This report qualitatively discusses:
• 11 leading cell-based assay product suppliers including:
o ThermoFisher Scientific
o GE Healthcare
• 9 leading cell-based assay service providers including:
o Cell Assay Innovations (CAI)
• The future trends and outlooks in the cell-based assay market including:
o Organoid technology
o 3D bioprinting
o Label-free systems
o Induced pluripotent stem cells (IPSCs)
• Strengths, weaknesses, opportunities and threats of the global cell-based assay market
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.